PHARMAC seeks clinical feedback on its cost-utility analysis methodology.
Explore the source record for details and available documents.
Cost-Benefit Analysis↗
Biomedical subjects
Peter Moodie
Publications and source records attributed to Peter Moodie.
PHARMAC and statins--getting the best population health gains.
Explore the source record for details and available documents.
Drug Utilization Review↗
PHARMAC and EpiPen for anaphylaxis.
Explore the source record for details and available documents.
Adrenergic beta-Agonists↗
PHARMAC and erythropoietin for cancer patients.
Explore the source record for details and available documents.
Anemia↗
More from PHARMAC on long-acting insulin analogues: insulin glargine now funded.
Explore the source record for details and available documents.
Diabetes Mellitus↗
PHARMAC's response on clopidogrel.
Explore the source record for details and available documents.
Clopidogrel↗
More on PHARMAC and tobacco control in New Zealand.
Explore the source record for details and available documents.
Bupropion↗
PHARMAC responds on TNF inhibitors for inflammatory arthritis.
Explore the source record for details and available documents.
Antirheumatic Agents↗
PHARMAC's response on temozolomide and funding costly medicines that prolong life shortly.
Explore the source record for details and available documents.
Antineoplastic Agents, Alkylating↗
PHARMAC responds on long-acting insulin analogues.
Explore the source record for details and available documents.
Cost-Benefit Analysis↗
PHARMAC responds to Stewart Mann on dihydropyridine calcium channel antagonists.
Explore the source record for details and available documents.
Calcium Channel Blockers↗
PHARMAC responds to Richard Milne on discounting health benefits and costs.
Explore the source record for details and available documents.
Cost-Benefit Analysis↗
PHARMAC welcomes debate.
Explore the source record for details and available documents.
Conflict of Interest↗
PHARMAC responds to the RMI's editorial.
Explore the source record for details and available documents.
Altruism↗
PHARMAC and tobacco control in New Zealand: two licensed funded options are already available.
Explore the source record for details and available documents.
Administration, Cutaneous↗
Response to 'Exceptional circumstances and heart transplantation' letter.
Explore the source record for details and available documents.
Drug Approval↗
PHARMAC responds on tolterodine for overactive bladder.
Explore the source record for details and available documents.
Benzhydryl Compounds↗